Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Clinical trials

WHO joins drive to make all clinical trial data publicly available

The World Health Organization is putting pressure on drug manufacturers to disclose all clinical trial data on a publicly accessible database.

The World Health Organization (WHO) puts pressure on drug manufacturers to make clinical trial data publicly accessible

Source: Thorkild Tylleskar / Wikimedia Commons

The World Health Organization set up its International Clinical Trials Registry Platform to create a network of national clinical data register sites across the world

The World Health Organization (WHO) has issued an official statement to encourage pharmaceutical companies to disclose clinical trial results on a publicly accessible database following concerns that negative results are kept out of the public domain.

“Concerns have been raised that there may be selective publication of trials dependent on their results, with particular concern that trial results which may be viewed as ‘negative’, are less likely to be submitted, or accepted, for publication in the scientific literature or made public in other ways,” says WHO in the draft statement.

WHO says it wants details of any trial to be available to the public, free and on a searchable register before any person receives the first medical intervention. The data should be updated and the final results routinely available within 18 months of the trial ending. The results should also appear in a peer-reviewed journal within the 18-month deadline, it has proposed.

The statement, which was out for public consultation until 15 November 2014, follows the creation of the WHO International Clinical Trials Registry Platform, a global network of national clinical data registries.

WHO says there is evidence that a substantial number of clinical trials remain unreported several years after study completion, even in the case of large randomized clinical trials.

The move was welcomed by the Royal Pharmaceutical Society’s chief scientist Jayne Lawrence. “We fully support public access to clinical trial data, which is vital to calculating the potential benefits and harms of medicines to patients. As pharmacists, improving our knowledge of the safety of medicines is central to what we do and this relies heavily on the ready access to clinical trial data.”

The Guild of Healthcare Pharmacists (GHP) says the draft statement, will set “a strong global standard for clinical trial reporting”.

But the GHP wants the declaration to include potential sanctions if drug companies fail to meet the deadlines. “Although we agree with the statement there appears to be enough loopholes that it may not have the desired result, and without sanctions how enforceable would it be?”

The GHP is also worried that the data may be hard to find even if they are publicly accessible. “If the registry is buried deep within a website so that only those who know it exists can find it, that would meet the letter of the statement if not the spirit,” the GHP says in its response to the consultation document. “Then it would not matter if negative results were posted.” 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067188

Readers' comments (1)

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.